Zhejiang Haisen Pharmaceutical Co Ltd

Zhejiang Haisen maintains a strong liquidity position, with a current ratio of 11.01, indicating that it holds significantly more current assets than current liabilities. However, the company reported negative free cash flow of -10.56 million CNY, driven by capital expenditures of -152.26 million CNY, which suggests a heavy investment in long-term assets. The company's liquidity risk is assessed as medium, primarily due to its negative net cash position after subtracting total debt.

In terms of profitability, Zhejiang Haisen reported a return on equity (ROE) of 9.1% and a return on assets (ROA) of 8.33%. These figures are strong relative to the industry median, indicating efficient use of equity and assets to generate profit. The company's net income of 135.88 million CNY and operating income of 156.45 million CNY further support its profitability.

Zhejiang Haisen's revenue is concentrated in a single business segment, with no disclosed geographic diversification. The company's operations are primarily based in China, and its revenue is entirely derived from domestic sources. This concentration increases exposure to local economic and regulatory risks.

The company's growth trajectory is mixed. While revenue for the latest period was 532.26 million CNY, the outlook for the current fiscal year (FY) and the next FY is not explicitly provided. However, the significant capital expenditures suggest a strategic focus on long-term growth and capacity expansion. The company's dilution risk is assessed as low, with no near-term pressure from share issuance or dilutive events.

Zhejiang Haisen has not disclosed any recent material events, such as regulatory filings or earnings call transcripts, that would indicate significant changes in its business strategy or financial position. The absence of recent events suggests a stable but potentially less dynamic business environment.

Zhejiang Haisen Pharmaceutical Co Ltd (001367.SZ) has undergone a formal classification update, establishing its primary activity as Pharmaceuticals within the broader Healthcare economic sector. This structural definition provides a clearer framework for analyzing the company's operational focus and market positioning. Concurrently, the firm’s risk profile has been initialized with specific assessments. Dilution risk is currently rated as low, suggesting a stable capital structure with minimal immediate threat of share value erosion from new issuances. In contrast, liquidity risk has been assessed at a medium level. This indicates that while the company is not in immediate distress, investors should monitor cash flow dynamics and trading volume to ensure sufficient market depth for large transactions. These updates reflect a foundational step in the company's financial tracking, moving from unclassified status to a defined sector and risk posture. The absence of analyst coverage or index membership in the current data profile suggests that market attention remains limited, making these internal risk metrics particularly relevant for early-stage evaluation. [doc:001367.sz-ha-financials]